- Home
- BRBR vs EXEL Comparison
BRBR vs EXEL Comparison
Compare BRBR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRBR
- EXEL
- Stock Information
- Founded
- BRBR 2019
- EXEL 1994
- Country
- BRBR United States
- EXEL United States
- Employees
- BRBR N/A
- EXEL N/A
- Industry
- BRBR Packaged Foods
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRBR Consumer Staples
- EXEL Health Care
- Exchange
- BRBR Nasdaq
- EXEL Nasdaq
- Market Cap
- BRBR 8.8B
- EXEL 9.8B
- IPO Year
- BRBR 2019
- EXEL 2000
- Fundamental
- Price
- BRBR $62.96
- EXEL $43.04
- Analyst Decision
- BRBR Strong Buy
- EXEL Buy
- Analyst Count
- BRBR 18
- EXEL 18
- Target Price
- BRBR $77.56
- EXEL $38.76
- AVG Volume (30 Days)
- BRBR 2.8M
- EXEL 3.9M
- Earning Date
- BRBR 05-05-2025
- EXEL 05-13-2025
- Dividend Yield
- BRBR N/A
- EXEL N/A
- EPS Growth
- BRBR 49.75
- EXEL 237.58
- EPS
- BRBR 2.14
- EXEL 2.20
- Revenue
- BRBR $2,192,100,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- BRBR $17.77
- EXEL $10.39
- Revenue Next Year
- BRBR $11.06
- EXEL $10.74
- P/E Ratio
- BRBR $29.39
- EXEL $19.53
- Revenue Growth
- BRBR 18.91
- EXEL 24.49
- 52 Week Low
- BRBR $48.06
- EXEL $20.40
- 52 Week High
- BRBR $80.67
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- BRBR 42.52
- EXEL 59.93
- Support Level
- BRBR $60.09
- EXEL $42.21
- Resistance Level
- BRBR $63.84
- EXEL $43.75
- Average True Range (ATR)
- BRBR 2.07
- EXEL 1.60
- MACD
- BRBR -0.02
- EXEL -0.09
- Stochastic Oscillator
- BRBR 45.48
- EXEL 53.96
About BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channels including club, food, drug and mass, eCommerce, convenience and specialty.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.